Gossamer Bio is trading at $9.12 (-5.01%), with no clear company-specific catalyst identified. - An October 26 report covered Chardan reiterating its Buy rating and noted physician concerns about potential seralutinib safety signals and financing-related liquidity pressure; it did not link these points to the decline. - Major U.S. indexes were higher, so broad-market weakness does not explain the move. Available evidence does not establish a specific catalyst.